Phase II study to determine the anti-tumor activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in esophageal cancer.

Hans Prenen Sanjeev Deva Bhumsuk Keam Colin R Lindsay Iwona Lugowska James Chih-Hsin Yang Federico Longo Maria J de Miguel Luken Mariano Ponz-Sarvisé Myung-Ju Ahn Mahmut Gümüş Stephane Champiat Antoine Italiano Sebastien Salas Ruth Perets Cagatay Arslan Byoung Chul Cho Stefan Evers Christophe Boetsch Daniel Marbach David Dejardin Nassim Sleiman Caroline Ardeshir Muriel Richard Jehad Charo Anton Kraxner Nino Keshelava Volker Teichgräber Victor Moreno

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

FAP-IL2v plus atezolizumab demonstrated clinical activity and was tolerable in patients with previously treated esophageal SCC.

Keyphrases